Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients.

ABSTRACT:

Background

A single non-invasive gene expression profiling (GEP) test (AlloMap®) is often used to discriminate if a heart transplant recipient is at a low risk of acute cellular rejection at time of testing. In a randomized trial, use of the test (a GEP score from 0-40) has been shown to be non-inferior to a routine endomyocardial biopsy for surveillance after heart transplantation in selected low-risk patients with respect to clinical outcomes. Recently, it was suggested that the within-patient variability of consecutive GEP scores may be used to independently predict future clinical events; however, future studies were recommended. Here we performed an analysis of an independent patient population to determine the prognostic utility of within-patient variability of GEP scores in

SUBMITTER: Crespo-Leiro MG 

PROVIDER: S-EPMC4600291 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature